EMCC European Monitoring Centre on Change

Sanofi

Company/Organisation:
Sanofi

Geographic Location

Country: European Union
Location of affected unit(s): France, Germany, other EU countries

Company

Sector: Manufacturing
Manufacture of pharmaceuticals, medicinal chemical and botanical products
21.10 - Manufacture of basic pharmaceutical products
Number Employed: 100000

Employment Effects

Announcement Date: 26-06-2020
Planned Job Reductions min: 1680
Planned Job Reductions max: 1680
Type of Restructuring: Internal restructuring
Employment Effect Start: 01-09-2020
Foreseen End Date: 30-09-2023
Other Job Reduction Measures: 1680

Additional Information

The French pharmaceutical giant Sanofi has announced a restructuring plan for its R&D activities and support functions that will result in 1,680 jobs cuts in the next three years in Europe, mainly in France where 1,000 job cuts are expected. The job reductions will affect support functions, sales and research-related platforms. No plant closures are to be expected. This plan, which will be spread over three years, is not linked to the consequences of Covid-19. It corresponds to a new strategy announced in December 2019. The aim is to make €2 billion in savings and to concentrate on a few promising niches. On the agenda: the end of research in diabetes, one of its traditional core businesses, as well as in the cardiovascular field. A worldwide restructuring was recorded in 2011 (1,400 to 3,000 job cuts in R&D, announced in 2011).

Sources: